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http://www.biomedcentral.com/1471-2334/13/75RESEARCH ARTICLE Open AccessInclusion of the benefits of enhanced cross-
protection against cervical cancer and prevention
of genital warts in the cost-effectiveness analysis
of human papillomavirus vaccination in the
Netherlands
Tjalke A Westra1*, Irina Stirbu-Wagner2, Sara Dorsman2, Eric D Tutuhatunewa1, Edwin L de Vrij1, Hans W Nijman3,
Toos Daemen1, Jan C Wilschut1 and Maarten J Postma4Abstract
Background: Infection with HPV 16 and 18, the major causative agents of cervical cancer, can be prevented
through vaccination with a bivalent or quadrivalent vaccine. Both vaccines provide cross-protection against
HPV-types not included in the vaccines. In particular, the bivalent vaccine provides additional protection against
HPV 31, 33, and 45 and the quadrivalent vaccine against HPV31. The quadrivalent vaccine additionally protects
against low-risk HPV type 6 and 11, responsible for most cases of genital warts. In this study, we made an analytical
comparison of the two vaccines in terms of cost-effectiveness including the additional benefits of cross-protection
and protection against genital warts in comparison with a screening-only strategy.
Methods: We used a Markov model, simulating the progression from HPV infection to cervical cancer or genital
warts. The model was used to estimate the difference in future costs and health effects of both HPV-vaccines
separately.
Results: In a cohort of 100,000 women, use of the bivalent or quadrivalent vaccine (both at 50% vaccination
coverage) reduces the cervical cancer incidence by 221 and 207 cases, corresponding to ICERs of €17,600/QALY
and €18,900/QALY, respectively. It was estimated that the quadrivalent vaccine additionally prevents 4390 cases of
genital warts, reducing the ICER to €16,300/QALY. Assuming a comparable willingness to pay for cancer and genital
warts prevention, the difference in ICERs could justify a slightly higher price (~7% per dose) in favor of the
quadrivalent vaccine.
Conclusions: Clearly, HPV vaccination has been implemented for the prevention of cervical cancer. From this
perspective, use of the bivalent HPV vaccine appears to be most effective and cost-effective. Including the benefits
of prevention against genital warts, the ICER of the quadrivalent HPV vaccine was found to be slightly more
favourable. However, current decision-making on the introduction of HPV is driven by the primary cervical cancer
outcome. New vaccine tenders could consider the benefits of cross-protection and the benefits of genital warts,
which requires more balanced decision-making.
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Figure 1 Schematic representation of the progression-of-
disease Markov models simulating the progression to cervical
cancer (A) and genital warts (B). Individuals progress or regress
from one health state to another according to disease-specific
transition probabilities (solid lines) or women can remain in the
same health state during consecutive cycles (dotted lines). Vaccine
efficacy was modelled by reducing the risk of infection. Cycle length
was set at 6 months’.
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Cervical cancer is one of the most common cancers
worldwide. It is caused by persistent infection with high-
risk Human Papillomavirus (HPV) [1]. In Europe, two
prophylactic HPV vaccines are available, a bivalent and a
quadrivalent vaccine. The bivalent ASO4-adjuvanted vac-
cine (“Cervarix”; GlaxoSmithKline) provides protection
against infection with HPV16 and 18. The quadrivalent
amorphous aluminium hydroxyphosphate sulphate adju-
vanted vaccine (“Gardasil” or “Silgard”; sanofi pasteur/
Merck Sharp & Dohme), also protects against HPV 6 and
11, in addition to HPV16 and 18. HPV16 and 18 are the
two major oncogenic HPV types and are responsible for
approximately 70% of cervical cancer cases worldwide [2].
HPV6 and 11 are low-risk HPV types; these viruses are
responsible for most of the cases of genital warts [3]. Ob-
viously, the choice of which vaccine to use will depend on
various factors, including the efficacy, safety and cost-
effectiveness of the vaccines.
In the Netherlands, the decision of implementing HPV
vaccination in the context of the National Immunization
Program (NIP) has been based on the prevention of cer-
vical cancer followed by a vaccine tender offered by the
two pharmaceutical companies. Although, in the context
of the Dutch drug reimbursement system, the cost of
the vaccination – for both vaccines – is listed at €105
per dose, substantial price reductions are likely to be
granted by the vaccine manufacturers. Therefore the
predominant focus is on the actual price of the vaccines,
and relevant clinical differences between both vaccines
are not taken into account. These differences relate to
the vaccines’ cross-protective efficacies against other,
non-vaccine, high-risk HPV types and the protection
against genital warts [4-6]. We argue that the decision
of which vaccine to use within a country-specific im-
munization program should be made by taking these
differences explicitly into account. In particular, the
willingness-to-pay for cancer and genital warts might
differ and can as such influence the acceptable cost-
effectiveness ratio.
In the Netherlands, approximately 600 new cases of
cervical cancer are diagnosed annually. Furthermore, the
incidence of genital warts is estimated at approximately
85.8 and 121.6 per 100,000 among men and women, re-
spectively [7]. Previously, several studies have estimated
that the implementation of HPV vaccination for Dutch
teenage girls, at 12 years of age, is a cost-effective inter-
vention at around €20,000 per quality-adjusted life year
(QALY) gained [8-12]. This was estimated irrespective of
which specific vaccine was used [13]. The present paper
aims to determine the costs and health outcomes of
HPV vaccination of 12-year-old girls for both vaccines
individually, considering not only the benefits of pre-
venting cervical cancer but also those of preventinggenital warts, in the context of the current cervical can-
cer screening program. In particular, the clinical benefits
and the incremental cost-effectiveness ratios (ICERs) for
both vaccines were estimated. Also, the price difference
between both vaccines was estimated to achieve equal
ICERs. Note that several governments, including the
Dutch and UK governments,, initially did not consider
the potential benefits of protection against genital warts
in their decision which vaccine to choose and thus the
HPV vaccine was introduced only on the basis of the
prevention of cervical cancer.
Methods
Model
A previously published Markov model for HPV infection
and cervical cancer was modified to take the additional
burden of genital warts into account [11]. The initial
model structure (Figure 1A) and input data (Additional
file 1) have been described in detail previously [11]. In the
current modified model, the potential cross-protection
benefits of both vaccines can be considered, since multiple
HPV-types (e.g. HPV16, 18, 31, 33, 45, other high-risk
HPV types and other low-risk HPV types) are included in
the design. In addition, the modified model simulates the
progression of HPV infection to genital warts for two ca-
tegories of HPV types: “6/11” and “other low-risk types”
(Figure 1B). The transition probabilities from “susceptible”
to “HPV-infected” to “genital warts” were adapted from
literature (Table 1 and Additional file 1) [14]. The




Mean and/or range Reference
Normal to HPV 6/11¥ 0 – 0.007 model
calibration
Normal to lrHPV¥ 0 – 0.04 model
calibration
HPV 6/11 to warts 0.34 [14]












Treatment costs cancer Mean (€)
CIN 1 1,483 [11]
CIN 2 1,718 [11]
CIN 3 1,868 [11]
Cervical cancer stage 1 19,114 [11]
Cervical cancer stage 2 20,762 [11]
Cervical cancer stage 3 20,762 [11]
Cervical cancer stage 4 26,528 [11]
Treatment costs warts Mean (€)
GP 114 Table 3
STI clinic 285 Table 3
GP + STI clini 338 Table 3
QALY-losses Mean
CIN 1 0.026 [11]
CIN 2 0.010 [11]
CIN 3 0.080 [11]
Cervical cancer stage 1 0.03 [11]
Cervical cancer stage 2 0.10 [11]
Cervical cancer stage 3 0.10 [11]
Cervical cancer stage 4 0.38 [11]
Genital warts 0.018 [20]
Vaccine characteristics Bivalent Quadrivalent
Efficacy HPV 16/18 95% 95% [23]
Efficacy HPV 6/11 0% 95% [23]
Cross-protection HPV 31 79% 57% [4,5]
Cross-protection HPV 33 46% 0% [4,5]
Cross-protection HPV 45 76% 0% [4,5]
Duration of protection lifelong lifelong [25]
Vaccination costs per dose €105 €105
¥ transition probabilities are age dependent.
* 6-months’ probability of moving from one health state to another.
NA = not applicable; GP = general practitioner; STI = sexually transmitted
infection; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus.
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HPV-prevalence and genital warts incidence (Table 2)
[7,15-17]. The model was used to estimate the clinical and
economical benefits of vaccination with either the bivalent
or the quadrivalent HPV vaccine in the context of the NIP,
in addition to the current Dutch cervical cancer screening
program. Note that it was assumed that neither the sensi-
tivity of the screening program nor the attendance is
changed by the implementation of HPV vaccination.
Burden of disease
Table 2 gives an overview of the age-specific numbers of
reported cases of genital warts in women treated by GPs
and STI-clinics, annually. In the Netherlands, the inci-
dence of genital warts in the total female and male po-
pulation is on average approximately 11,500 and 8,100
annually, respectively [7]. Of these cases approximately 9%
are treated in clinics for sexually-transmitted infections.
No direct coherent Dutch data are available about the
treatment costs of genital warts and the quality of life du-
ring an episode of genital warts. Therefore, costs were
estimated from different sources, including national data-
bases, literature and expert opinions [7]. The medical
costs include general practitioner (GP) visits, specialist vi-
sits, treatment costs and pharmacists’ fees. The utility
losses of genital warts were adapted from literature [18].
Total GP treatment costs of genital warts were esti-
mated from the Netherlands Information Network of
General Practice (LINH). Data available through LINH
are based on electronic medical records from about 85
general practices, spread throughout the country. DataTable 2 Average annual age-specific number of reported
genital warts cases (2002-2007) in women by GP or STI
clinic [7]
Age group GP STI clinic Total
10 – 14 432 1 433
15 – 19 1,120 139 1,259
20 – 24 1,911 437 2,348
25 – 29 2,267 210 2,070
30 – 34 1,978 92 1,392
35 – 39 1,343 48 787
40 – 44 753 34 385
45 – 49 368 17 181
50 – 54 167 14 79
55+ 196 4 200
Total 10,536 996 11,533
GP = general practitioner, STI = sexually transmitted infections.
Table 3 Detailed build-up of the average per female







GP + STI clinic
(€)
GP visits 28 50.40 0 50.40
Telephone consult 14 2.80 0 2.80
Specialist visits¥ 59 0 224.20 224.20
Podophylotoxin 35 42.80 42.80 42.80
Imiquimod 100 6.80 6.80 6.80
Pharmacist fee 5.50 5.50 5.50 5.50
Prescription 5.50 5.50 5.50 5.50
Chirurgical
treatment¥¥
10.00 0.45 0 0.45
Total direct costs 114 285 338
GP = general practitioner, STI = sexually transmitted infections.
¥ In the Netherlands a medical specialist receives a fixed price for the
treatment of genital warts.
¥¥ Adapted from Woodhall et al. [20].
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ristics such as age, sex, degree of urbanization, as well
as medical information on consultations, prescriptions,
referrals, and diagnoses. GPs participating in the LINH
network are instructed to use ICPC-1 codes for every
patient contact. Based on ICPC-codes X91 and Y76,
probable cases of genital warts in 2007, 2008 and 2009
were identified. A total of 935 (491 female and 444 male)
patients with genital warts were identified over the
period 2007-2009. Medication was prescribed in 80%
and 91% for the female and male patients, respectively.
Per treated patient an average of 1.7 prescriptions were
counted (range 1 to 22). Podophylotoxin and imiquimod
were the drugs mostly used, in 90% and 5% of the cases,
respectively. Women diagnosed with genital warts visited
their GP slightly more often than men, an average of 1.8
(range 1 to 20) and 1.5 (range 1 to 18) visits per person,
respectively. Furthermore, on average, 0.2 (range 0 to 4)
telephone consultancies per person diagnosed with geni-
tal warts were made. Surgical removal (CTG Dutch hos-
pital costing codes 13012, 13047, 13048) of the warts
was performed with 37 patients, requiring an average of
1.2 surgical interventions per patient. Finally, 115 (12%)
patients were sent to a medical specialist, most often a
gynaecologist (i.e. 40% of female patients) or a derma-
tologist (i.e. 60% of female and 90% of male patients).
Unit costs were adapted from Oostenbrink et al. and
from the Dutch Health-Care Insurance Board [19]. Sum-
ming up all the costs, the average per-patient GP-treat-
ment costs were estimated at €114 and €106 for females
(Table 3) and males, respectively. The treatment costs of
genital warts within an STI-clinic (€285 per case) were
obtained from expert consultation.
It has been shown that the quality of life during an
episode of genital warts decreases to 0.944 [20,21]. This
corresponds to a QALY loss of approximately 0.018 per
case of genital warts [18].
Estimates of the costs and QALYs, for the different (pre-)
cancer stages, were adapted from our previous publication
(Table 1) [11]. For incidence data, treatment costs and
quality-of-life estimates for cervical cancer and pre-cancer
stages, we refer to our previous publication [11].
Vaccine characteristics
The bivalent as well as the quadrivalent HPV vaccine
shows a high efficacy against infection with HPV16 and
18, the virus types included in both vaccines. In line with
our previous studies, we conservatively assumed a 95%
efficacy against HPV16 and HPV18 infection for both
vaccines [9]. Furthermore, both vaccines induce cross-
protection against other oncogenic HPV-types [4,5,22-24].
Since the bivalent vaccine induces a higher degree of
cross-protection than the quadrivalent vaccine (Table 1),
vaccine-specific cross-protection efficacies were explicitlytaken into account. Finally, it was assumed, that both vac-
cines induce lifelong protection [25]. Total vaccination
costs were set at €315 per vaccinated woman (including 3
doses and administration costs). Note that relevant lower
vaccine prices are paid within the Dutch NIP, and pro-
bably also in other national immunization programmes,
after tendering. Therefore, vaccination costs were reduced
in sensitivity analysis. No utility losses due to side effects
were considered.
Cost-effectiveness analyses
Differences in costs and effects were estimated by fol-
lowing a cohort (100,000 women) during life twice, once
as a partly (e.g. 50%) vaccinated (bivalent or quadriva-
lent) cohort and once as an unvaccinated cohort. For all
situations it was assumed that 90% of all women attend
the current Dutch cervical cancer screening program at
least once during life according to the “pre-vaccine-era”
5-yearly compliance rate of 80%. No changes in the
screening program structure or compliance rates were
assumed for the vaccinated cohort. The model tracks
the total number of cases (e.g. cervical cancer, cervical
premaligancies, and genital warts), costs, life-years (LY)
gained and changes in QALYs. By summing up all the
costs, LY gained or QALYs, the net costs, LYs and
QALYs gained/lost were determined for both options.
Subsequently, the difference between the vaccinated and
unvaccinated cohort was determined. The incremental
cost-effectiveness ratio (ICER) was calculated by dividing
the incremental costs by the incremental LY or QALYs
gained. In the Netherlands, interventions with an ICER
below €20,000 per QALY gained are generally considered
as being cost-effective. Future costs and health effects
were discounted at 4% and 1.5%, respectively, reflecting
the Dutch guidelines for cost-effectiveness research [26].
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case findings to other countries, we also performed sen-
sitivity analyses at costs and health outcomes discount
rates of both 3%. Finally, the vaccine prices of the vac-
cines were varied to achieve equal ICERs for both.
Sensitivity analyses
The robustness of the outcomes were analyzed in uni-
variate sensitivity analyses. As there is uncertainty about
the duration of vaccine-induce protection, vaccine price,
cross-protection, and the treatment costs of genital
warts, these parameters values were varied in univariate
sensitivity analyses. To provide insight in the impact of
possible additional herd-immunity benefits on our fin-
dings a certain degree of herd-immunity was incorpo-
rated in our model. In particular, based on a previous
study of Bogaards et al., we estimated a relative risk re-
duction among unvaccinated women for developing cer-
vical cancer of 33%, aligning a 50% vaccine uptake [8].
This risk reduction was applied to both the unvaccinated
male and female populations for both cervical cancer
and genital warts. As the herd-immunity benefit is high-
ly sensitive to the vaccination coverage, these benefits
were estimated for different coverages; i.e. for 50%, 70%
and 90% coverage, the relative risk reductions were
estimated at 33%, 55% and 84%, respectively. Finally, to
enhance the transferability of our finding to other coun-
tries the discount rate and screening compliance was
varied in sensitivity analyses. As the Netherlands and
Belgium are unique in discounting health effects with a
lower rate compared to costs, the discount rates for both
health effects and costs were also varied independently
in the sensitivity analyses. Furthermore, in the Nether-
lands 90% of women are screened at least once during
life. Compared to other countries this is a relative high
coverage and therefore we decreased this coverage to
70%, 50% and 30% in sensitivity analysis.
In addition to the impact of the above parameters on
the estimated ICER, we also determined the price diffe-
rence between the two vaccines under conditions of equal
ICERs, not only for the base case, but also for the different
options analyzed in the sensitivity analyses.
Results
Clinical results
Introduction of HPV vaccination for 12-year-old girls in
the model, at a 50% vaccination coverage reduces the
annual HPV16/18-related cervical cancer incidence by
198 cases, independent of which vaccine is used. Due to
the benefits of cross-protection [5], the bivalent vaccine
will prevent 23 cases of cervical cancer induced by one
of the other high-risk HPV types while, due to a lower
level of cross-protection [6] thusfar documented, the
quadrivalent vaccine will prevent 9 cases due to cross-protection. So, in total we estimated that the bivalent
and quadrivalent HPV vaccine prevent 221 and 207
cases of cervical cancer, respectively. Furthermore, both
vaccines will prevent cervical premalignancies, the bi-
valent vaccine 106 CIN1, 203 CIN2 and 264 CIN3, and
the quadrivalent vaccine 91 CIN1, 182 CIN2 and 237
CIN3. In addition, the quadrivalent vaccine will prevent
annually 4,390 cases of genital warts.
Cost-effectiveness of HPV vaccination
Notably, 1,524 (646 if discounted) or 1,430 (606 if dis-
counted) life years will be gained when the bivalent or
quadrivalent HPV vaccine are being used, respectively.
When all the above health benefits are taken together, in
total 1,815 (790 if discounted) or 1,803 (824 if dis-
counted) QALYs are estimated to be gained by using the
bivalent or the quadrivalent vaccine, respectively. In par-
ticular, for the bivalent vaccine 709 discounted QALYs
are gained by providing protection against HPV16/18-
induced cervical (pre-)malignancies and 81 discounted
QALYs are gained due to cross-protection. For the
quadrivalent vaccine, 709, 33 and 82 discounted QALYs
are gained due to protection against HPV16/18-induced
(pre-)malignancies, cross-protection and prevention of
genital warts, respectively. Furthermore, vaccination
with the bivalent vaccine results in a discounted cost-
saving of €1,641,000 by providing protection against
HPV16/18-induced (pre-)malignancies and discounted
cost-saving of €211,000 due to cross-protection. The
quadrivalent vaccine results in discounted cost-savings
of €1,641,000, €84,000 and €570,000 due to protection
against HPV16/18-induced (pre-)malignancies, cross-
protection, and prevention of genital warts, respectively.
The total vaccination costs are estimated at €15M per
year in the Netherlands.
Considering only the benefits of prevention of HPV16/
18-related disease, the ICER was estimated at €19,900
per QALY or €24,300 per LY gained (€41,900/QALY or
€52,800/LY if discounted at 3%). When the benefits of
cross-protection and protection against genital warts are
taken into account, the ICER of the bivalent and quadri-
valent vaccines were estimated at €17,600 per QALY or
€21,500 per LY gained (€36,900/QALY or €46,500/LY if
discounted at 3%) and €16,300 per QALY or €22,700 per
LY gained (€31,800/QALY or €49,600/LY if discounted
at 3%), respectively.
Sensitivity analyses
In the univariate sensitivity analyses, the ICER for the bi-
valent HPV vaccine ranged from €2,200 to €97,100 per
QALY gained. The ICER for the quadrivalent vaccine ran-
ged from €1,000 to €73,100 per QALY gained. Figure 2
shows the upper and lower limit of the ICER upon varia-
tion of individual parameter values. Figure 2 shows that
Figure 2 Incremental cost-effectiveness ratio of varying parameter values in univariate sensitivity analyses.
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of protection, herd-immunity and the discount rate for
health benefits. Figure 3 provides a detailed overview of
the cost-effectiveness of HPV vaccination for the four
abovementioned scenarios. Also, we considered a best-
case (i.e. vaccine price €45/dose, lifelong protection, herd
immunity and discount rates costs and health effects at
0%) and a worst-case scenario (i.e. vaccine price €105,
20-years protection, no herd immunity, and high discount
rates cost and health effects at 4%). HPV vaccination was
estimated to be cost-saving (irrespective of the HPV vac-
cine) in the best-case scenario. In the worst-case scenario
the ICER was €81,800/QALY (€107,700/LY) or €66,500/
QALY (108,200/LY), for the bivalent and quadrivalentFigure 3 Cost-effectiveness (Euro/QALY and Euro/LY) for the bivalent
Euros per quality-adjusted life years gained; circles: quadrivalent vaccine; sqHPV vaccine, respectively. Finally, the cost effectiveness of
HPV vaccination was found to be more favourable in a set-
ting with a moderate or poor screening program (Figure 4).
Price differential between the bivalent and quadrivalent
HPV vaccine
The per-dose price differential between both vaccines
was estimated such that the cost-effectiveness of the bi-
valent vaccine would equal that of the quadrivalent vac-
cine (€16,300 per QALY gained). Note that, here, we
considered an equal willingness-to-pay for prevention of
cancer and genital warts. In the base-case, we estimated
that, based on a list price of €105/dose, the bivalent vac-
cine has to be €6.90 per dose less expensive comparedand quadrivalent HPV vaccine. Black: Euros per life year gained; red:
uares: bivalent vaccine.
Figure 4 Cost-effectiveness and price differential of HPV vaccines in setting with a reduced screening compliance. Left panel shows
cost-effectiveness of HPV vaccination. Black: € per life-year gained; red: € per quality-adjusted life years gained. Circles: quadrivalent vaccine;
squares: bivalent vaccine. Right panel: price differential between bivalent and quadrivalent HPV vaccine. Blue squares: price differential
considering the life-years gained; red dots: idem if quality-adjusted life years gained are considered.
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(€14, if discounted at 3%). This price difference was
most sensitive to assumptions about herd immunity,
treatment costs of genital warts, exclusion of the benefits
of either cross-protection or genital warts, vaccination
costs and, again, the discount rate for health benefits
(Figures 5 and 6). The price differential ranged from
minus €2,80, if only life years gained were considered
(i.e. the bivalent vaccine might be more expensive), to al-
most €11 if future health outcomes are discounted at
4%. Indeed, consideration of herd immunity resulted in
a larger price difference between both vaccines to
achieve equal ICERs. A 33% reduction in incidence of
genital warts and cervical cancer among unvaccinated
females and males resulted in a price differential of ap-
proximately €15 per dose. If vaccine coverage would fur-
ther increase to 90%, the price differential increased to
€16 per dose. Finally, if the bivalent vaccine provides an
extended duration of protection compared to the qua-
drivalent vaccine, as has been hypothesized by Einstein
et al. [27], the results were in favour of the bivalent vac-
cine. In particular, assuming lifelong protection for the
bivalent vaccine and 20 or 40 years for the quadrivalentFigure 5 Sensitivity analyses on the price differential of the bivalent
that the quadrivalent vaccine can be more expensive to be as cost-effectivvaccine, we estimated a price differential of €24 and €1
per dose, respectively. Finally, in the worst-case scenario,
the price differential was estimated at €21.
In settings with a moderate or poor screening program
the estimated ICER was more driven by the health gains
of providing protection against cervical cancer. Conse-
quently, the price differential diminishes in settings with
a higher burden of cervical cancer, often accompanying
a relatively poor screening program (Figure 4).
There are three scenarios in which the bivalent vaccine
may have a higher price compared to the quadrivalent
vaccine to be equally cost-effective. These scenarios in-
clude the conditions in which (i) only LY gained are con-
sidered, (ii) the quadrivalent vaccine provides a shorter
duration of protection, and (iii) prevention of genital
warts are not taken into account.
Discussion
Currently, there are two registered prophylactic HPV
vaccines, a bivalent vaccine and a quadrivalent vaccine.
To decide which vaccine could best be used in countries’
national immunization programs, an analytical compari-
son in terms of cost-effectiveness between both vaccinesand quadrivalent HPV-vaccines. A positive price difference indicates
e as the bivalent vaccine.
Figure 6 Price differential for the quadrivalent vaccine to be as cost-effective as the bivalent vaccine. Blue squares indicate the price
differential considering the life-years gained and red dots indicate the same if quality-adjusted life years gained are considered.
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study was to make a specific comparison between the bi-
valent and the quadrivalent HPV vaccines, taking the spe-
cific characteristics of both vaccines explicitly into
account. These include not only the benefits of protection
against HPV16 and 18, but also those of cross-protection
against other high-risk HPV types and, for the low-risk
HPV types, protection against genital warts. Note that, al-
though differences in immunogenicity between both vac-
cines have been reported [24], the clinical relevance of this
has not been demonstrated yet. Even though we con-
ducted the study for the situation in the Netherlands, the
general conclusions of our analyses are likely to apply,
with minor modifications, to other European countries
and the USA, because of strong similarities in HPV preva-
lence and implementation of prophylactic vaccination
programs in these countries.
From our base-case analyses, it follows that use of the
bivalent HPV vaccine gives the highest reduction in cer-
vical cancer incidence. Consequently, the highest num-
ber of life-years gained was obtained by implementing
the bivalent vaccine, resulting in a more favourable ICER
compared to that obtained with the quadriavalent vac-
cine (€21,500/LYG vs €22,700/LYG). This implies that
the bivalent vaccine might be €2.80 more expensive if
only LYs are considered. Considering QALYs gained on
the basis of protection against (pre-)cervical malignan-
cies and genital warts, the quadrivalent vaccine provided
the highest health gain. The ICER of the quadrivalent
vaccine was estimated to be more favourable than that
of the bivalent vaccine at €16,300/QALY gained vs.€17,600/QALY. This implies that the quadrivalent vac-
cine can be approximately €7 per dose (based at a list
price of €105/dose) more expensive than the bivalent
vaccine to be equally cost-effective.
The ICERs of both vaccines were found to be particu-
larly sensitive to the vaccine price (range: €5,600 - 17,600/
QALY), the duration of protection (range: €16,300 -
48,900/QALY), the discount rate for health benefits (range:
€5,300 - 97,100/QALY) and, to herd-immunity benefits
(range: €10,700 - 17,600/QALY). In most scenarios, the
ICER (€/QALY) of the quadrivalent vaccine remained
more favourable than that of the bivalent vaccine. This dif-
ference, as argued above, may justify a slightly higher vac-
cine price for the quadrivalent vaccine. Interestingly,
without discounting, the bivalent vaccine results in a
slightly higher QALY gain than the quadrivalent vaccine,
despite the benefits in terms of prevention of genital warts
of the latter. This illustrates that the health gains of pre-
vention of cervical cancer prevention are highly sensitive
to the discount rate applied. Furthermore, it is important
to note that the acceptable price differential between both
vaccines highly depends on the vaccine price applied for
the reference vaccine. In particular, in the base-case
(bivalent vaccination costs was €105/dose), the price differ-
ential was estimated at €7 per dose. Reducing the vaccin-
ation costs of the bivalent vaccine to, for example, €45 per
dose, the price differential decreases to €4. Possible lower
vaccine costs will further reduce the price differential
between both vaccines. Inclusion of additional herd-
immunity benefits resulted in an increased price difference
between both vaccines primarily due to the benefits of
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males. Interestingly, the absolute herd-immunity benefit in
females will be highest if vaccine coverage is moderate,
while in males the herd-immunity benefit will highest
when vaccine uptake is high.
In our study, the indirect effects could not be directly
considered as a static model was used. The use of static
models for infectious disease modelling has been criti-
cised by us and others [28-30]. However, in balancing
complexity and transparency, static models are still of
major importance and can be used for initial assess-
ments. Here, we included the potential herd-immunity
benefits based on a previous Dutch modelling study
[23]. Further research should be directed to develop a
dynamic transmission model including the most impor-
tant high- and low-risk HPV types. Another limitation
of the current study is that potential additional health
benefits of providing protection against other than cer-
vical cancers were not included. The inclusion of these
cancers will further improve the ICER for both vaccines.
Consequently, price differentials between both vaccines
might diminish [18], as the benefit of providing protec-
tion against genital warts will play a less prominent role.
Finally, we did not perform any probabilistic sensitivity
analysis (PSA). The use of PSA is highly recommended
as it provides some insight in the certainty of the out-
comes. However, comparing the PSAs of different vac-
cines is rather critical as potentially a highly favourable
option (upper limit 95% confidence interval) of one vac-
cine is compared with a rather unfavourable option
(lower limit 95% confidence interval) of the other vac-
cine. For that reason we currently didn’t embark on a
formal PSA, but rather performed an extensive deter-
ministic sensitivity analysis.
Our results are generally in line with the findings of
others. In particular, several studies estimated that the
bivalent HPV vaccine resulted in the highest reduction
in cervical cancer incidence due to the additional bene-
fits of cross-protection [28,30]. However, as only the
quadrivalent vaccine provides protection against genital
warts, the decision which vaccine to use is not that
straightforward. From a health-economic perspective,
the most cost-effective vaccine should be preferred con-
sidering both the health gains of providing protection
against cervical cancer and genital warts. Several studies
made this type of comparison between both vaccines
[25-28]. Here, we estimated that a €6.70 (7%) price dif-
ferential, in favour of the quadrivalent HPV vaccine,
resulted in equal ICERs. This justifiable price difference
between both vaccines estimated in the present study is
slightly different from that found in other studies [31].
For example, Jit et al. estimated that the bivalent vaccine
should be approximately 25% less expensive [32]. Indeed,
even larger discrepancies have been reported [31,33].The difference between our study and those of others
can be explained by various factors. Firstly, as mentioned
above, we used a static model in which herd-immunity
benefits are not directly taken into account. As indicate
above, inclusion of herd-immunity benefits results in
an increased price difference (e.g., the price difference
reaches a maximum of approximately 16% when herd-
immunity is taken into account). Secondly, we included
vaccine-specific cross-protection against high-risk HPVs
in our analyses. As there is evidence that the bivalent
vaccine is more cross-protective than the quadrivalent
vaccine [5,6], this results in a smaller price difference.
Finally, according to health-economic guidelines in the
Netherlands, future health benefits are discounted with a
relatively low discount rate of 1.5%, and therefore, the
health benefits of cervical cancer are devalued less than
in most other countries. Nevertheless, in general we can
conclude that in western countries a higher vaccine
price for the quadrivalent vaccine is justified due to the
additional benefits of providing protection against geni-
tal warts.
In contrast, Demarteau et al. estimated that for Taiwan
a higher vaccine price for the bivalent vaccine is justified
[34]. The difference between this study and the studies
performed in western countries can be primarily explained
by the higher incidence of cervical cancer in Taiwan. Due
to the potentially higher effectiveness of the bivalent vac-
cine in providing protection against cervical cancer a rele-
vantly higher health gain might be obtained in settings
with a high burden of cervical cancer. In most western
countries the burden of cervical cancer has already been
dramatically reduced since the introduction of cervical
cancer screening. Consequently, in these settings the ben-
efits of providing protection against genital warts are pre-
dominant and the ICER of the quadrivalent vaccine is
even more sensitive to the inclusion of the benefits of pro-
viding protection against genital warts than found in our
study. This illustrates that the decision which vaccine to
use on health-economic grounds will highly depend on
the disease burden of cervical cancer versus the burden of
genital warts.
Conclusion
In conclusion, the results of our study demonstrate that
HPV vaccination is a cost-effective intervention in the
Netherlands. Clearly, HPV vaccination has been imple-
mented for the prevention of cervical cancer. From this
perspective, use of the bivalent HPV vaccine appears to
be most effective and most cost-effective in prevention
of cervical cancer. This is primarily due to the broader
cross-protective capacity of the bivalent vaccine, com-
pared to the quadrivalent vaccine, against high-risk HPV
types not included in the vaccines. However, if the po-
tential benefits of providing protection against genital
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From a health economic perspective, a coherent analytic
comparison of the bivalent and quadrivalent HPV vaccines
could be made and to consider costs and benefits of
cross-protection against other high-risk HPV types not
included in the vaccines as well as those of protection
against genital warts. From a health care decision-making
perspective, these analyses – next to other criteria – can
then be compared to the initial intention of cancer pre-
vention underlying introduction of the vaccination in local
national vaccination programs. This will then provide a
more balanced view than cost-comparison alone.
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